For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Transcatheter Aortic Valve Replacement (TAVR), also referred as Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive surgical procedure repairs the valve without removing the old, damaged valve. Instead, it wedges a replacement valve into the aortic valve's place. Normally valve replacement method requires an open heart procedure with a sternotomy, in which the chest is surgically separated for the treatment. The TAVR procedures can be done through very small openings that leave all the chest bones in place.
Scope of the Report:
This report studies the Transcatheter Aortic Valve Replacement (TAVR) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Transcatheter Aortic Valve Replacement (TAVR) market by product type and applications/end industries.
The classification of Transcatheter Aortic Valve Replacement (TAVR) includes transfemoral approach, transapical approach and others. The proportion of transfemoral approach in 2016 is about 84%.
Transcatheter Aortic Valve Replacement (TAVR) is widely used for aortic stenosis, aortic regurgitation and other diseases. The most proportion of Transcatheter Aortic Valve Replacement (TAVR) is used for aortic regurgitation, and the proportion in 2016 is 75%.
Europe is the largest consumption place, with a consumption market share nearly 53% in 2016. Following Europe, North America is the second largest consumption place with the consumption market share of 40%.
Market competition is not intense. Edwards Lifesciences, Medtronic, St. Jude Medical, Boston Scientific, Meril Life Sciences, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Transcatheter Aortic Valve Replacement (TAVR) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Transcatheter Aortic Valve Replacement (TAVR).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Edwards Lifesciences
- St. Jude Medical
- Boston Scientific
- Meril Life Sciences
- Bracco (HLT)
- JenaValve Technology
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Transfemoral Approach
- Transapical Approach
Market Segment by Applications, can be divided into
- Aortic Stenosis
- Aortic Regurgitation